Introducing the LIDODERM® Formulary Hotline and EndoFormularyLink.com.

2 new resources to provide you with up-to-date LIDODERM formulary status for specific plans in your area.

LIDODERM Formulary Hotline FAQ

What is the LIDODERM Formulary Hotline phone number?
The phone number for the LIDODERM Formulary Hotline is 1-888-LidoHCP (1-888-543-6427).

What are the hours of operation for the hotline?
Live operators will be available from 8am–5pm EST, Monday to Friday. Calls placed to the Formulary hotline before and after the hours of operation will receive an automated message asking to call back during designated hours of operation for assistance with their formulary questions.

What information will the Formulary Hotline operators provide to a HCP who calls?
Live operators will provide the formulary status of LIDODERM for the requested managed care plan by the caller.

Will the Formulary hotline help process Prior Authorizations for plans that require them for LIDODERM?
No. The Formulary hotline operators will provide formulary status only (including if LIDODERM requires a prior authorization) for a specific plan. The operators will not assist in the completion or processing of any prior authorization paperwork. Operators will be able to provide the web site address and contact phone number for the plan in question to allow the caller to gather the necessary information and paperwork to complete the prior authorization.

Will the Formulary hotline provide the co-pay amount for LIDODERM for the requested plan?
No. The Formulary hotline operators will not be able to provide the actual co-pay amount for LIDODERM for the requested managed care plan. As co-pays vary by employers, the operators will direct the caller to contact the employer or health plan directly to get the co-pay amounts and will offer to provide the employer or plan contact numbers if requested.

Will the Formulary hotline provide comparative formulary information regarding other PHN medications?
No. Only LIDODERM formulary status (not comparative information) will be provided to the caller when they call to inquire about LIDODERM for a specific plan.

Will HCPs be able to request promotional materials, samples or a rep visit when calling the Formulary hotline?
All requests for promotional materials, samples or a rep visit will be forwarded to Endo daily and will be processed within 48 hours.


Important Safety Information

LIDODERM® (lidocaine patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.

LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.

Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.

Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.

Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.

Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.

Allergic reactions, although rare, can occur.

During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.

When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.

Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

Before prescribing LIDODERM, please refer to the full Prescribing Information.